"The data we will present during the WCIRDC this year show that there may be complementary mechanisms of action between icovamenib and approved GLP-1-based therapies that have the potential to provide a synergistic response and improved efficacy for patients," the company said.
Biomea Fusion Says In Preclinical Experiments, Icovamenib Enhanced Beta Cell Function And Responsiveness Of Human Islets To GLP-1-Based Therapies
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated